PARD (Poniard Pharmaceuticals) Institutional Ownership: 0.00% (As of Jul. 06, 2026)


What is Poniard Pharmaceuticals Institutional Ownership?

Poniard Pharmaceuticals PARD Institutional Ownership is 0.00% as of Jul. 06, 2026.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Poniard Pharmaceuticals's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Poniard Pharmaceuticals's Insider Ownership is 2.31%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Poniard Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 77.41%.

Poniard Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Institutional Ownership Chart

Poniard Pharmaceuticals Historical Data

The historical data trend for Poniard Pharmaceuticals can be seen below:

2020-11-30 2020-12-31 2021-01-31 2021-02-28 2021-03-31 2021-04-30 2021-05-31 2021-06-30 2021-07-31 2021-08-31
Institutional Ownership 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01

Poniard Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.00% mean?
Poniard Pharmaceuticals (PARD) has a Institutional Ownership of 0.00% as of Jul. 06, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' Institutional Ownership too high?
Poniard Pharmaceuticals' current Institutional Ownership is 0.00%.
How does Poniard Pharmaceuticals' Institutional Ownership compare to OBMP and NSPX?
Poniard Pharmaceuticals' Institutional Ownership of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current Institutional Ownership is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current Institutional Ownership of 0.00%. The current Institutional Ownership is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current Institutional Ownership is 0.00% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.